Related Experiment Videos
MAPKs: new targets for neurodegeneration.
1Department of Biochemistry & Molecular Biology, Neuroscience Research Centre, Merck, Sharp & Dohme Research Laboratories, Terlings Park, Harlow, Essex CM20 2QR, UK. sarah_harper@merck.com
Expert Opinion on Therapeutic Targets
|April 2, 2003
Summary
Targeting specific cell death pathways with kinase inhibitors offers a promising therapeutic strategy for neurodegenerative diseases like Parkinson's and Alzheimer's. This review examines mitogen-activated protein kinases (MAPKs) as potential targets to halt disease progression.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Neurodegenerative diseases like Alzheimer's and Parkinson's lack effective disease-modifying therapies.
- Aberrant cell death is increasingly recognized as a central mechanism in neurodegeneration.
- Kinases involved in cell death pathways represent potential therapeutic targets.
Purpose of the Study:
- To review the role of three mitogen-activated protein kinase (MAPK) families in neurodegenerative diseases.
- To examine the evidence for extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38 MAPKs in disease states and models.
- To discuss the therapeutic potential and challenges of kinase inhibitors.
Main Methods:
- Literature review of studies investigating MAPK pathways in neurodegenerative disease models.
- Analysis of evidence for pathway activation in disease states.
- Evaluation of data on kinase inhibitors and their effects.
Main Results:
- Evidence for the activation of ERK, JNK, and p38 MAPK pathways in various neurodegenerative conditions.
- Discussion of available inhibitors for these pathways.
- Identification of potential therapeutic benefits and associated risks of kinase inhibition.
Conclusions:
- Targeting specific MAPK pathways involved in cell death may offer a novel therapeutic approach for neurodegenerative diseases.
- Further research is needed to optimize kinase inhibitor therapies and mitigate side effects.
- Mitogen-activated protein kinases (MAPKs) are critical targets for future neurodegenerative disease treatments.